ARVN's first FDA-approved PROTAC degrader validates its technology, while a diverse pipeline targeting cancer and neurological disorders offers further growth potential.

– Data showed improvements in an objective measure of impaired eye movement associated with Parkinson's disease, with a correlation between reductions in LRRK2 cerebrospinal fluid (CSF) biomarkers to these changes in oculomotor function and changes in synaptic biomarkers –

NEW HAVEN, Conn., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that novel biomarker data from a Phase 1 clinical trial of ARV-102 in participants with Parkinson's disease will be presented as late-breaking oral and poster presentations at the 2026 International Congress of Parkinson's Disease and Movement Disorders® (MDS), taking place October 4-8, 2026, in Seoul, Korea.

NEW HAVEN, Conn., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the Company granted an option to purchase 64,766 shares of common stock (the “Option Award”) and 42,388 restricted stock units (“RSU”) to one newly hired employee (the “RSU Award”). The Option Award and RSU Award were each granted as of September 28, 2026 (the “Grant Date”) in accordance with Nasdaq Listing Rule 5635(c)(4) and not pursuant to Arvinas' stock incentive plan.

– ARV-6723 is an investigational, oral PROTAC designed to degrade HPK1, a negative regulator of immune activation, in advanced solid tumors –

Arvinas, Inc. (ARVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that that management will participate in fireside chats at the following upcoming investor conferences:

NEW HAVEN, Conn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the Company granted 45,696 restricted stock units (“RSU”) to one newly hired employee (the “RSU Award”). The RSU Award was granted as of August 31, 2026 (the “Grant Date”) and in accordance with Nasdaq Listing Rule 5635(c)(4) and not pursuant to Arvinas' stock incentive plan.